Zacks: Brokerages Expect Sunesis Pharmaceuticals, Inc. (SNSS) to Post -$0.25 EPS

Brokerages expect that Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) will post earnings per share (EPS) of ($0.25) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Sunesis Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.33) and the highest is ($0.17). Sunesis Pharmaceuticals reported earnings per share of ($0.44) in the same quarter last year, which indicates a positive year-over-year growth rate of 43.2%. The company is expected to issue its next earnings report on Thursday, March 8th.

On average, analysts expect that Sunesis Pharmaceuticals will report full-year earnings of ($1.58) per share for the current fiscal year, with EPS estimates ranging from ($1.66) to ($1.48). For the next fiscal year, analysts forecast that the firm will report earnings of ($0.96) per share, with EPS estimates ranging from ($1.16) to ($0.80). Zacks Investment Research’s EPS averages are an average based on a survey of analysts that cover Sunesis Pharmaceuticals.

Sunesis Pharmaceuticals (NASDAQ:SNSS) last posted its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.06). During the same quarter last year, the business posted ($0.62) earnings per share.

A number of research firms have recently issued reports on SNSS. Cantor Fitzgerald reiterated a “hold” rating and issued a $3.00 target price on shares of Sunesis Pharmaceuticals in a research note on Wednesday, September 27th. Cowen reissued a “hold” rating on shares of Sunesis Pharmaceuticals in a report on Thursday, November 2nd. Zacks Investment Research downgraded Sunesis Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, October 4th. Oppenheimer started coverage on Sunesis Pharmaceuticals in a report on Tuesday, November 21st. They issued an “outperform” rating and a $7.00 price target for the company. Finally, UBS Group started coverage on Sunesis Pharmaceuticals in a report on Monday, November 20th. They issued an “outperform” rating for the company. One research analyst has rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $3.75.

In related news, major shareholder Mpm Oncology Impact Management purchased 25,300 shares of the business’s stock in a transaction that occurred on Thursday, November 2nd. The shares were acquired at an average price of $2.59 per share, with a total value of $65,527.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Dayton Misfeldt bought 400,000 shares of the stock in a transaction that occurred on Friday, October 27th. The stock was acquired at an average price of $2.00 per share, for a total transaction of $800,000.00. The disclosure for this purchase can be found here. In the last three months, insiders purchased 506,800 shares of company stock worth $1,091,282. Company insiders own 10.21% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of SNSS. Wells Fargo & Company MN increased its position in Sunesis Pharmaceuticals by 77.4% in the 2nd quarter. Wells Fargo & Company MN now owns 41,851 shares of the biopharmaceutical company’s stock valued at $113,000 after acquiring an additional 18,254 shares during the period. Virtu KCG Holdings LLC acquired a new position in shares of Sunesis Pharmaceuticals during the 2nd quarter valued at $208,000. Vanguard Group Inc. increased its position in shares of Sunesis Pharmaceuticals by 4.1% during the 2nd quarter. Vanguard Group Inc. now owns 605,759 shares of the biopharmaceutical company’s stock valued at $1,635,000 after purchasing an additional 23,819 shares during the period. Finally, Balyasny Asset Management LLC acquired a new position in shares of Sunesis Pharmaceuticals during the 2nd quarter valued at $5,400,000. Hedge funds and other institutional investors own 38.21% of the company’s stock.

Shares of Sunesis Pharmaceuticals (NASDAQ SNSS) opened at $4.01 on Friday. The company has a quick ratio of 1.84, a current ratio of 1.84 and a debt-to-equity ratio of -0.34. Sunesis Pharmaceuticals has a 12 month low of $1.82 and a 12 month high of $4.45. The stock has a market capitalization of $136.96, a PE ratio of -2.29 and a beta of 1.53.

TRADEMARK VIOLATION WARNING: This story was originally posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this story on another website, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this story can be viewed at https://sportsperspectives.com/2018/01/12/zacks-brokerages-expect-sunesis-pharmaceuticals-inc-snss-to-post-0-25-eps.html.

Sunesis Pharmaceuticals Company Profile

Sunesis Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML).

Get a free copy of the Zacks research report on Sunesis Pharmaceuticals (SNSS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Sunesis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply